Disulfiram/Copper Induces Immunogenic Cell Death and Enhances CD47 Blockade in Hepatocellular Carcinoma

Immunogenic cell stress and death

(2022) Guido Kroemer et al.   NATURE IMMUNOLOGY

Anticancer effects of disulfiram in T‐cell malignancies through NPL4‐mediated ubiquitin–proteasome pathway

(2022) Cunte Chen et al.   JOURNAL OF LEUKOCYTE BIOLOGY

CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies

(2022) Renée Bouwstra et al.   Clinical and Translational Medicine

Disulfiram: a novel repurposed drug for cancer therapy

(2021) Chen Lu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Valosin-Containing Protein (VCP)/p97: A Prognostic Biomarker and Therapeutic Target in Cancer

(2021) Susan Costantini et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo

(2021) Rocio Montes de Oca et al.   MOLECULAR CANCER THERAPEUTICS

First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges

(2021) Alessandro Rizzo et al.   Expert Review of Gastroenterology & Hepatology

Targeting CD47 for cancer immunotherapy

(2021) Zhongxing Jiang et al.   Journal of Hematology & Oncology

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

(2021) Thomas Yau et al.   LANCET ONCOLOGY

Induction of immunogenic cell death in radiation-resistant breast cancer stem cells by repurposing anti-alcoholism drug disulfiram

(2020) Ting Sun et al.   Cell Communication and Signaling

Icaritin Exacerbates Mitophagy and Synergizes with Doxorubicin to Induce Immunogenic Cell Death in Hepatocellular Carcinoma

(2020) Zhuo Yu et al.   ACS Nano

The combination of disulfiram and copper for cancer treatment

(2020) Hong Li et al.   DRUG DISCOVERY TODAY

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

(2020) Lorenzo Galluzzi et al.   Journal for ImmunoTherapy of Cancer

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma

(2020) Hirofumi Yoshino et al.   PLoS One

Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy

(2020) Hanzhang Zhu et al.   CELLULAR ONCOLOGY

The intrinsic immunogenic properties of cancer cell lines, immunogenic cell death, and how these influence host antitumor immune responses

(2020) Tania Løve Aaes et al.   CELL DEATH AND DIFFERENTIATION

Targeting immunogenic cell death in cancer

(2020) Asma Ahmed et al.   Molecular Oncology

A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer

(2019) Lucia D’Amico et al.   Journal for ImmunoTherapy of Cancer

Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade

(2019) Fangyuan Zhou et al.   ADVANCED MATERIALS

Process of immunogenic cell death caused by disulfiram as the anti-colorectal cancer candidate

(2019) Si-yuan You et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Upregulation of NPL4 promotes bladder cancer cell proliferation by inhibiting DXO destabilization of cyclin D1 mRNA

(2019) Bao-Sai Lu et al.   Cancer Cell International

Immunogenic cell death in cancer therapy: Present and emerging inducers

(2019) Jingyi Zhou et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade

(2019) Oliver Kepp et al.   OncoImmunology

Disulfiram’s anti-cancer activity reflects targeting NPL4, not inhibition of aldehyde dehydrogenase

(2019) Zdenek Skrott et al.   ONCOGENE

EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells

(2019) Vinay Sagar et al.   Cell Death & Disease

Targeted and Immune-Based Therapies for Hepatocellular Carcinoma

(2018) Tim F. Greten et al.   GASTROENTEROLOGY

Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4

(2017) Zdenek Skrott et al.   NATURE

HISAT: a fast spliced aligner with low memory requirements

(2015) Daehwan Kim et al.   NATURE METHODS

Key Steps in ERAD of Luminal ER Proteins Reconstituted with Purified Components

(2014) Alexander Stein et al.   CELL

Immune tolerance in liver disease

(2014) Ian N. Crispe   HEPATOLOGY

featureCounts: an efficient general purpose program for assigning sequence reads to genomic features

(2013) Y. Liao et al.   BIOINFORMATICS

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47

(2010) M. P. Chao et al.   Science Translational Medicine

edgeR: a Bioconductor package for differential expression analysis of digital gene expression data

(2009) M. D. Robinson et al.   BIOINFORMATICS